Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;10(1):34-41.
doi: 10.1111/andr.13097. Epub 2021 Aug 31.

Testosterone in males with COVID-19: A 7-month cohort study

Andrea Salonia  1   2 , Marina Pontillo  3 , Paolo Capogrosso  1   4 , Silvia Gregori  5 , Cristina Carenzi  1 , Anna Maria Ferrara  1 , Isaline Rowe  1 , Luca Boeri  1   6 , Alessandro Larcher  1 , Giuseppe A Ramirez  2   7 , Cristina Tresoldi  8 , Massimo Locatelli  3 , Giulio Cavalli  2   7 , Lorenzo Dagna  2   7 , Antonella Castagna  2   9 , Alberto Zangrillo  2   10 , Moreno Tresoldi  11 , Giovanni Landoni  2   10 , Patrizia Rovere-Querini  2   12 , Fabio Ciceri  2   13 , Francesco Montorsi  1   2
Affiliations

Testosterone in males with COVID-19: A 7-month cohort study

Andrea Salonia et al. Andrology. 2022 Jan.

Abstract

Background: Circulating testosterone levels have been found to be reduced in men with severe acute respiratory syndrome coronavirus 2 infection, COVID-19, with lower levels being associated with more severe clinical outcomes.

Objectives: We aimed to assess total testosterone levels and the prevalence of total testosterone still suggesting for hypogonadism at 7-month follow-up in a cohort of 121 men who recovered from laboratory-confirmed COVID-19.

Materials and methods: Demographic, clinical, and hormonal values were collected for all patients. Hypogonadism was defined as total testosterone ≤9.2 nmol/L. The Charlson Comorbidity Index was used to score health-significant comorbidities. Descriptive statistics and multivariable linear and logistic regression models tested the association between clinical and laboratory variables and total testosterone levels at follow-up assessment.

Results: Circulating total testosterone levels increased at 7-month follow-up compared to hospital admittance (p < 0.0001), while luteinizing hormone and 17β-estradiol levels significantly decreased (all p ≤ 0.02). Overall, total testosterone levels increased in 106 (87.6%) patients, but further decreased in 12 (9.9%) patients at follow-up, where a total testosterone level suggestive for hypogonadism was still observed in 66 (55%) patients. Baseline Charlson Comorbidity Index score (OR 0.36; p = 0.03 [0.14, 0.89]) was independently associated with total testosterone levels at 7-month follow-up, after adjusting for age, BMI, and IL-6 at hospital admittance.

Conclusions: Although total testosterone levels increased over time after COVID-19, more than 50% of men who recovered from the disease still had circulating testosterone levels suggestive for a condition of hypogonadism at 7-month follow-up. In as many as 10% of cases, testosterone levels even further decreased. Of clinical relevance, the higher the burden of comorbid conditions at presentation, the lower the probability of testosterone levels recovery over time.

Keywords: COVID-19; SARS-CoV-2; comorbidities; follow-up; male; testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Scatter plot, vertical. Sex‐related hormonal analyses at baseline compared to 6‐month follow‐up in COVID‐19 patients. (A and D) Total testosterone. (B and E) Follicule‐stimulating hormone (FSH). (C and F) Luteinizing hormone (LH). *p = 0.01; ****p < 0.0001
FIGURE 2
FIGURE 2
Interaction test assessing the probability (%) that circulating total testosterone levels could increase according to Charlson Comorbidity Index (CCI) score at hospital admittance
See this image and copyright information in PMC

Comment in

References

    1. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID‐19. Nat Med. 2020;26:1017‐1032. - PMC - PubMed
    1. Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID‐19 in older adults: a systematic review and meta‐analysis. BMC Geriatr. 2021;21:321. - PMC - PubMed
    1. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS‐CoV‐2 patients: a systematic review and meta‐analysis. mBio. 2021;12:e03647‐20. - PMC - PubMed
    1. Corona G, Pizzocaro A, Vena W, et al. Diabetes is most important cause for mortality in COVID‐19 hospitalized patients: systematic review and meta‐analysis. Rev Endocr Metab Disord. 2021;22:275‐296. - PMC - PubMed
    1. Roychoudhury S, Das A, Jha NK, et al. Viral pathogenesis of SARS‐CoV‐2 infection and male reproductive health. Open Biol. 2021;11:200347. - PMC - PubMed